• The established and most prominent method of visualizing bladder cancer, white light, lacks the clarity needed to detect finer margins of tumors, which increases the likelihood of recurrence
• The more recent, improved method, blue light, provides clarity yet introduces cost barriers to adoption
• Imagin Medical’s i/Blue Imaging(TM) System combines the best of both methods, clarity and real-time visualization at a lower cost
• The system is highly adaptable to current endoscopic instruments, making it easy and affordable to implement

For over 30 years, the standard of visualizing bladder cancer during surgery has been white light illumination through an endoscopic procedure called a cystoscopy. When performing a cystoscopy, the surgeon uses the scope and white light to identify and remove the tumors that protrude above the bladder. Therein lies the problem, as the finer edges that need to be resected are not always clearly defined and tumors that lay flat against the bladder wall are often not visible using this technology. This inability to resect completely may contribute to the over 50% recurrence rate of bladder cancer.

While these limitations can be successfully overcome with the use of blue light and an imaging agent, this type of illumination has the drawback of not showing the cancer in real time. This requires surgeons to switch between white and blue light, making the procedure more challenging.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on changing the standards of visualizing cancer during minimally invasive procedures, is intent on addressing these issues through its innovative technology that has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System eliminates the need to switch between the white and the blue light images by displaying both images side-by-side on a single screen.

The system is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. It therefore enables better visualization of tumors and margins, allowing for a more accurate resection.

The control unit is state-of-the-art, featuring a dual-wavelength light source, two-channel camera control unit, data recorder, and power supply. Simultaneous white and blue light illumination of the bladder allows for the side-to-side monitor images.

Additionally, Imagin Medical’s system is adaptable to most endoscopes already being used in hospitals. That means healthcare units that want to convert to the i/Blue Imaging(TM) System would not require new endoscopic equipment, resulting in cost savings.

The primary focus of Imagin Medical’s i/Blue Imaging(TM) System is bladder cancer, the sixth most prevalent type of cancer in the United States with one of the highest recurrence rates. The technology has the potential for use in other minimally invasive procedures, with plans already in motion to implement this system for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources.

Imagin Medical has made the transition from the development stage to manufacturing by contracting the services of Lighthouse Imaging, an FDA-registered and ISO 13485:2016-certified manufacturer, to accelerate production.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Agreement between RYAH, THC Lab outlines parameters for launch of RYAH’s IoT dose-measuring Smart-Inhaler
• Aim of agreement is to reach hundreds of pharmacies, establish RYAH as the market standard for vaporizing
• The two companies also planning to work together on controlled research, bioavailability testing projects

RYAH Group, a leading digital health care analytics and technology company, has entered into a research-and-distribution arrangement THC Lab, which specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis (https://ibn.fm/UPk8j). The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy and the Netherlands. “We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical cannabis currently estimated at only 10% in Italy and around 20% in the Netherlands,” said THC Lab sales manager Andrea Ferrari. “Our aim is to reach out to hundreds of pharmacies and establish RYAH as the market standard for vaporizing. We are extremely excited about this new partnership and see tremendous synergies with our other commercial as well as scientific activities in the medical cannabis sector.” THC Lab appears to be an ideal partner for RYAH as the company expands globally. THC Lab has a vast network of compounding pharmacies, cannabis clinics and physicians, cannabis patient associations and pharmaceutical distributors. THC Lab will also support RYAH in further optimizing its Smart-Inhaler by providing patients the ability to provide invaluable feedback regarding the device through an integrated, in-app feedback forum. In addition to distribution arrangements, the two companies are planning to work together in a number of controlled research and bioavailability testing projects focused on studying the effectiveness of plant-based medicines in patients with various medical conditions. “We are thrilled by this cooperation as this gives us also the opportunity to contribute to the success and development of RYAH by providing our scientific input and carrying out joint observational studies on our patients,” said THC Lab CEO and technical director Dr. Annunziata Lombardi. A leading data and technology company, RYAH is pioneering the development of dose-measuring, plant-based delivery methods that capture vital consumption data. RYAH uses that essential data to create breakthrough discoveries aimed at advancing the validity of plant-based medicine and providing researchers with the tools needed to develop life-altering therapies. The company is developing a suite of IoT devices, including a dry-herb inhaler device paired with the software that is capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant-dose management. Its robust AI platform is created to aggregate and correlate HIPAA-compliant medical data intended to help doctors and patients personalize plant-based treatments to predict and obtain improved treatment outcomes. The essential data collected by the company can also be used by pharmacies, clinics, growers, dispensaries and Licensed Processors (“LPs”) to monitor and manage plant strain effects on patients. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities
• The company has research and development operations in North America and Europe and an operational focus in Germany
• XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine
• The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19
• XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications; the company intends to complete human pilot studies evaluating these products in 2021
• The company has two agreements in place focused on psychedelic compounds, a promising new class of API with strong potential for the treatment of mental health conditions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

• Commercialization of infectious disease diagnostics
• Clinical validation of transdermal and sublingual drug formulations
• Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (“CE-IVD”) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

• Rotigotine transdermal patch for Parkinson’s disease
• CBD oral/sublingual strip for treatment resistant epilepsy
• THC oral/sublingual strip for anorexia/nausea
• CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

• An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
• An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• BRSF paving way with next wave of innovation for neurology: e-tattoos
• Acceptance of telemedicine, AI here to stay following pandemic
• Scientists have learned how to read brain waves using minimally invasive, implantable, four-channel micro EEG to better monitor continuous seizures

The COVID-19 pandemic has accelerated several changes to American culture, many of which appear to be here to stay. According to Harvard experts, some of those changes include movement towards a cashless society, increased remote work, the decline of brick-and-mortar retail, and a new approach to health that includes an acceptance of telemedicine and artificial intelligence (“AI”) (https://ibn.fm/f9IJ5). Brain Scientific (OTCQB: BRSF) is positioned to benefit from that growing acceptance of AI as it focuses on modernizing brain diagnostics. Early in 2020, Elon Musk announced work on brain interface tech to turn humans into a genius super race. While Musk grabs the spotlight for all things high tech, his brain-computer chip company Neuralink went down as one of many overhyped AI ideas for the year (https://ibn.fm/E9mtr). Musk’s idea might sound like science fiction, allowing an external computer to input data as though the mind is nothing more than a computer processor, but the reverse is a reality. Elon Musk has dreams of fixing anything wrong with the brain, but before that can be achieved, the problem first needs to be identified and understood. Currently, scientists are working to understand what causes Parkinson’s disease, Alzheimer’s disease, dementia and other neurological issues. The root of the problem must be discovered before the solution is created. The good news is that BRSF is making inroads in helping identify those problems. The company has unveiled a new initiative to develop a brain E-Tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. This provides 24/7 uninterrupted seizure monitoring, something that was unavailable previously with the bulky EEGs administered and overseen by specialized techs in hospitals. The EEG dates back to 1929 and has only seen drastic advances in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, co-founder and executive chairman at BRSF (https://ibn.fm/kP4jX). “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. “The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions,” he continued. “Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s e-Tattoo, answers are right around the corner.” BRSF is committed to modernize brain diagnostics through cutting edge technologies that narrow the widening gap of accessibility to much needed neurological care. In addition to its e-tattoo innovation, the company has received FDA clearance for two transformative EEG products — the NeuroCap(TM) and NeuroEEG(TM) —  that have the potential to disrupt the market, provide EEG accessibility and 24/7 EEG coverage where it was once unavailable. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Absorption vital component of product effectiveness
• CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
• Xceptol products offer CBD in format more in line with body’s natural bioactivity

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness. Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://ibn.fm/NlIT3). A product that claims some of the fastest rates on the market is worth paying attention to. Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers. Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://ibn.fm/iHNsR). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks. CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency. Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon. CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Gage opens its Grand Rapids, Michigan store — the company’s sixth provisioning center in the state
• Store offers more than 40 exclusive strains of flower in addition to variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products and more
• Gage has single focus: to curate highest-quality cannabis experience possible for its consumers

Gage Cannabis kicked off 2021 with a bang — opening its sixth provisioning center (dispensary) in Michigan and the first in West Michigan (https://ibn.fm/Un9Rc). Gage Cannabis is a leading high-quality craft cannabis brand in Michigan.

“As a lifelong resident of Grand Rapids, I’m thrilled to introduce my hometown to Gage,” said Drew McCarthy, store manager and a local media personality. “While the company prides itself on the three Cs — cannabis, culture and community — in my short time with the company I’ve witnessed a fourth C, caring. I’m proud to be part of a company that cares about its employees, cares about its products and cares about the community.”

At this time, the 4,018-square-foot store is only open to medical marijuana cardholders, with orders available for curbside pick-up only. The store offers more than 40 exclusive strains of flower in addition to a variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products, accessories and even apparel.

Gage has a single focus: to curate the highest-quality cannabis experience possible for its consumers (https://ibn.fm/mItNr). The company accomplishes this by growing its own plants in small batches using 100% hydroponic cultivation methods for sustainable and responsible operations. Every plant is handpicked, and then every plant undergoes Gage’s proprietary drying, trimming and curing process, with each step deliberately designed to deliver the best flower possible.

Gage selected Michigan to start its operations based on the state’s fast-growing legal cannabis market and consumer habits. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center, or dispensary, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open this year.

About Gage

Gage Cannabis Company is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the company’s founding partners have successfully built and grown operations with federal and state licenses including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).

For more information, visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE

• InsuraGuest goes live with Guesty, the world’s leading end-to-end short-term rental property management software
• Property managers who use Guesty to manage their short-term rentals: rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com
• Company’s success has hinged not only the caliber of management but even more so on the power of its proprietary software platform.
• The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality.

Technology has now become a key factor in the insurance industry, and it is generating significant changes. The combination of insurance and technology (insurtech) is disrupting the entire insurance industry by providing new cost saving solutions and better customer experiences. It is designed to deliver better processes and greater efficiencies utilizing advanced insurance technologies. A leader in the insurtech sector, InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF)  continues to expand an already impressive reach into multiple insurance markets. The company’s first target is the hospitality sector with intent to dominate what looks to be an incredibly lucrative sector. InsuraGuest Technologies’ latest landmark is the announcement that it has gone live on a vendor partnership with Guesty, the world’s leading end-to-end short-term rental property management software (https://ibn.fm/Fs82V). InsuraGuest will integrate with the Guesty property management software through its proprietary API, which will enable Guesty’s 60k US property managers to transfer certain liability exposures to the InsuraGuest carrier. By transferring certain liabilities to the InsuraGuest Hospitality Liability coverages, for a small fee of $11.95 per night (which is passed on to the guest), the covered short-term rental properties can lower their claim ratios and risk profiles, which may decrease their general liability and/or homeowners’ premiums. Alon Eitan, Guesty’s Director of Strategy & Business Development stated, “We are excited to launch our relationship with InsuraGuest. Providing our customers with access to vendors like InsuraGuest helps protect their properties while protecting their guests.” InsuraGuest Technologies is steamrolling the industry, signing agreements with property management systems and operators, continually expanding the reach of its network. The company’s success has hinged not only the caliber of management but even more so on the quality of its value proposition. With a solid foundation built on the power of its proprietary software platform, InsuraGuest Technologies intends to dominate multiple insuratech markets. Commenting on the latest partnership, Douglas Anderson, CEO and Chairman of InsuraGuest Technologies stated, “Being able to work with the world’s leading end-to-end short-term rental property management software company means InsuraGuest will have access to market its Hospitality Liability product to property managers who use Guesty to manage their short-term rentals; rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com.” The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality. The appeal is obvious to operators. Liability usually has limitations and high deductibles. When these incidents are covered by a property’s general liability insurance it could cost a facility more than the actual event and drive-up premiums. InsuraGuest provides a layer of protection that responds to the property directly when guests experience mishaps. Using InsuraGuest may decrease a property’s general liability premiums, thus saving money, time and aggravation for hotel and vacation rental operators. InsuraGuest is transforming the way insurance is delivered – digital insurance reimagined, reinvented, and revolutionized. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Mobile technology innovator Friendable is pioneering a new venue for marketing musicians and allowing fans more direct access to their favorite performers as part of an emerging trend in digital engagement
• Friendable’s Fan Pass app fills a void in the entertainment industry during the closure of in-person concert and convention venues during the COVID pandemic, providing an interactive stage for performers through a monthly app subscription
• Friendable has signed more than 700 artists since launching Fan Pass in July
• The company recently announced a growing list of “Pro Services” to help its entertainers build their brand online, ranging from logo design to set building
• The subscription includes an initial trial-basis offer, followed by a low monthly fee equating to a couple of song downloads

The year 2020 will undoubtedly be remembered in the annals of history for its social and political drama, an idea celebrated in social media memes that feature time travelers recoiling from the thought of visiting that particular point in time. One innovation to emerge from the year, however, was the advent of direct digital platform engagement between entertainers and their fans during a year when live, in-person performances were all but outlawed as a result of the COVID pandemic. The trend initially manifested as artists started posting brief performances on their social media channels to provide a bit of upbeat distraction during “coronavirus isolation,” ranging from Italian tenor Maurizio Marchini singing opera from his balcony and comedian Steve Martin playing banjo music from a glade of trees (https://ibn.fm/P26HI) to old-school rockers Blue Oyster Cult presenting a lockdown rendition of “Godzilla” with five band members streaming together from separate locations (https://ibn.fm/B2Qs0). The enthusiasm for such impromptu digital engagement led to its evolution as a way for fans missing out on music concerts and star-studded science fiction conventions to find live, real-time performances from their favorite artists online and even chat one-on-one with them for a modest price. Mobile technology and marketing innovators at Friendable (OTC: FDBL) are establishing themselves as pioneers in delivering this type of fan experience through a proprietary app available on Google Play and the Apple Store. Since launching in July, Friendable’s Fan Pass platform has added more than 500 artists to its roster. The company recently announced that it is enhancing its ability to provide musicians a customized stage by establishing its “Pro Services” offering for existing artists with plans to soon roll out the service to all new artists during their onboarding and sign-up process (https://ibn.fm/ArJCM). The Pro Services include logo design, website creation, social media communications, merchandising, set building and lighting, with plans to expand what is offered to artists as the platform grows. “Our vision for Fan Pass has always been one of supporting both the artists and their fans, and now that we have a variety of artists, live channels, performances and content it’s a natural fit to begin offering additional services that can only enhance each artist brand, as well as boost revenue opportunities on Fan Pass,” Friendable CEO Robert A. Rositano Jr. stated in making the announcement. “In many ways, we are similar to a venture capital firm that nurtures each of its startups with the tools for success; but, in our case, we don’t discriminate based on talent, ideas or stage of career.” Fan Pass offers initial access to subscribers for free on a trial basis, offering social media access to exclusive VIP experiences, interviews and behind-the-scenes content featuring favored artists, with monthly rates thereafter priced equal to a couple of song downloads. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers for free on a trial basis. Thereafter, subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, providing VIP access at a fraction of the cost of traditional face-to-face meetups. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Torrey Hills Capital is a leading investor and financial public relations firm that offers extensive expertise in investor relations, corporate communications and other market support operations
• The services provided to Imagin Medical will be overseen by Torrey Hills Founder and Principal Cliff Mastricola
• Imagin believes its proprietary imaging technology, the i/Blue Imaging System(TM), will establish a new standard of care in visualizing cancer during minimally invasive procedures
• Company’s current focus is bladder cancer, the 6^th most prevalent form of cancer and most expensive to treat

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has engaged the services of San Diego-based investor relations firm Torrey Hills Capital, Inc. to increase awareness of its products with an informed investor audience in both the U.S. and Canadian marketplaces.

Torrey Hills Capital is a leading investor and financial PR firm that specializes in small and microcap companies. Formed in 1998, the firm offers considerable expertise and experience in corporate communications, investor relations, non-deal roadshows, as well as other market support activities (https://ibn.fm/8cnR8).

Torrey Hills Capital will provide Imagin Medical with dedicated market awareness and investor relations services that will be overseen by Cliff Mastricola, founder and principal of the firm. Mastricola has extensive experience in advising and developing corporate finance strategies, especially debt and equity capital-related issues, as well as mergers and acquisitions, recapitalizations, valuations and helping private companies go public.

The agreement between Imagin and Torey Hills is subject to regulatory acceptance of applicable filings with the CSE. Signed for an initial period of three months at a monthly rate of $7,000, the agreement can be automatically extended if both parties are satisfied with the terms and achieved progress. Imagin also agreed to a one-time grant of 100,000 incentive stock options at a price of $0.49 (C$0.62) per share for a three-year period.

By contracting Torrey Hills Capital, Imagin Medical plans to increase public and investor awareness of its innovative imaging technology, the i/Blue Imaging System), that the company expects will establish a new standard of care in visualizing cancer during minimally invasive procedures. The company’s initial focus is bladder cancer, the sixth most prevalent forms of cancer in the United States and the most expensive one to treat, while also having one of the highest recurrence rates (https://ibn.fm/KdZpt).

The current standard of visualizing bladder cancer during surgery uses white light illumination, which is especially effective when it comes to visualizing cancerous tumors protruding above the bladder wall. However, with this method flat tumors look the same as normal tissue. This issue is successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used in real-time during surgery, and requires surgeons to constantly switch back and forth between white and blue light images to get perspective.

The proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time. Additionally, the technology is highly versatile and can be attached to most endoscopes on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.

According to Imagin Medical, this technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position the company as a leading provider of effective solutions in the global bladder cancer market, which is expected to reach $4.71 billion by 2026 (https://ibn.fm/tTWOf). Imagin Medical also intends to expand its technology for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast agents and illumination sources.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• San Francisco-based MAZAKALI is leveraging its extensive cannabis investment and fundraising advisory experience on the ongoing boom in the industry
• The company foresees the Cannabis complex becoming a trillion-dollar market as society continues to adopt the plant’s use for a large range of medical and industrial purposes
• The inauguration of President Joe Biden is ushering in an era of federal government in which cannabis-friendly officials are being named to key advisory positions in his cabinet and the Democratic Party
• Cannabis is currently legal for medical use in 35 U.S. states and permitted for adult-use in 15 states and the District of Columbia

Market watchers appear to consider liberalization of federal laws regarding cannabis to be a foregone conclusion now that the inauguration of President Joe Biden has taken place. That, in turn, is leading to rosy expectations for cannabis consumption — especially in light of the ongoing march of state-by-state legalization amid a growing acceptance of cannabis for adult-use as well as medicinal purposes. Cannabis marketplace facilitator MAZAKALI is helping investors seize opportunities to build profitable portfolios in this high growth industry while also assisting companies that are looking to raise capital to fuel their growth. The San Francisco-based capital adviser oversees an online investment marketplace that handles direct investments in a diverse field of vetted opportunities while also serving highly funded clients with personalized portfolio management and an Outsourced Cannabis Investment Officer (“OCIO”) service for asset managers. Cannabis plays a key role in MAZAKALI’s mission — in 2016 the company began working specifically to help investors place capital and to help companies raise capital. MAZAKALI’s GreenPapers(R) inform investors and operators through insights into deep trends in the cannabis complex, predicting in 2017 that significant federal reform would take place this year with a Democratic victory in the White House. “We had been following public opinion polls on (cannabis) legalization and noticed a fairly precipitous decline in the opposition to legalization. As an example, from 2007 through (20)17 we saw opposition decline from 60 to 40 percent and support increase even more, from 30 to nearly 60 percent,” MAZAKALI founder and CEO Sumit Mehta said during an interview with Jeremy Neilson, CEO of Assure (https://ibn.fm/ZVSkT). “We then looked at other states-led rights issues that eventually became legal at a federal level and we saw fairly similar trajectories,” Mehta added. “We saw a meaningful uptick in the states that were passing cannabis legalization measures between 2015 and 2017, and knew that the majority of Americans would soon have legal access to this plant with countless stories to share about its medical impact.  We expected that this would further bolster the public support that was building, fueled further as media was also becoming far less reticent to cover this increasingly destigmatized topic.” Cannabis is currently legal for medical use in 35 U.S. states and permitted for adult-use in 15 states (https://ibn.fm/W3Bw1). Its use has been adopted by a wide age range of consumers, particularly as older populations turn to cannabidiol (“CBD”) for over-the-counter pain relief and sleep aids (https://ibn.fm/9kTlt). In further support for investor confidence, observers have noted that President Biden appears to be stocking his cabinet with several key cannabis-friendly advisers. He has named a strong supporter of cannabis legalization as his nominee to lead the Democratic National Committee (“DNC”) (https://ibn.fm/Miclc). “It is likely that Cannabis will prove to be the best performing asset class over the next decade…Hemp will prove to be a major contribution to farmer livelihood as well as industrial and economic output, with the Cannabis complex likely a trillion-dollar market in the making,” MAZAKALI states as part of its advisory profile (https://ibn.fm/q2uwE). For more information, visit the company’s website at www.MAZAKALI.com. NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI